PRAB

Activities: Manufacturing Sustainability

Trending Articles

  1. Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
  2. Therapeutic: ensifentrine for chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
  3. Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
  4. Bringing biotech to the Baltics: the rise of Lithuania Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
  5. Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA

Upcoming event

ISPE Singapore

28-30 August 2024 | Conference and exhibition | Singapore See all

Related Content

Manufacturing

Wastewater recycling is a pathway to lower risk exposure and costs in pharmaceutical manufacturing

Without question, water consumption is becoming an area of increasing focus for pharmaceutical manufacturers who wish to position themselves as both responsible corporate citizens and profitable businesses, writes Mike Hook, Sales and Marketing Director at PRAB
Subscribe now